135 related articles for article (PubMed ID: 10888869)
1. Genetic testing and quality control in diagnostic laboratories.
Dequeker E; Cassiman JJ
Nat Genet; 2000 Jul; 25(3):259-60. PubMed ID: 10888869
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: report of a large European external quality assessment.
Dequeker E; Cassiman JJ
Eur J Hum Genet; 1998; 6(2):165-75. PubMed ID: 9781062
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and use of a synthetic quality control material, included in the European external quality assessment scheme for cystic fibrosis.
Berwouts S; Gordon JT; Rundell CA; Barton DE; Dequeker E
Hum Mutat; 2008 Aug; 29(8):1063-70. PubMed ID: 18470946
[TBL] [Abstract][Full Text] [Related]
4. Introduction to molecular cystic fibrosis testing.
Uphoff TS; Highsmith WE
Clin Lab Sci; 2006; 19(1):24-31. PubMed ID: 16617555
[TBL] [Abstract][Full Text] [Related]
5. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
6. Outcome of intracytoplasmic sperm injection for a couple in which the man is carrier of CFTR p.[R74W;V201M;D1270N] and p.P841R mutations and his spouse a heterozygous carrier of p.F508del mutation of the cystic fibrosis transmembrane conductance regulator gene.
Brugnon F; Bilan F; Heraud MC; Grizard G; Janny L; Creveaux I
Fertil Steril; 2008 Nov; 90(5):2004.e23-6. PubMed ID: 18703181
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?
Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C
Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492
[TBL] [Abstract][Full Text] [Related]
8. Carrier screening for cystic fibrosis in US genetic testing laboratories: a survey of laboratory directors.
Kaufman DJ; Katsanis SH; Javitt GH; Murphy JA; Scott JA; Hudson KL
Clin Genet; 2008 Oct; 74(4):367-73. PubMed ID: 18700896
[TBL] [Abstract][Full Text] [Related]
9. Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through screening.
Bobadilla JL; Farrell MH; Farrell PM
Adv Pediatr; 2002; 49():131-90. PubMed ID: 12214770
[No Abstract] [Full Text] [Related]
10. The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity.
Salvatore M; Falbo V; Floridia G; Censi F; Tosto F; Bombieri C; Castaldo G; Pignatti PF; Rosatelli MC; Taruscio D
Clin Chem Lab Med; 2007; 45(2):254-60. PubMed ID: 17311518
[TBL] [Abstract][Full Text] [Related]
11. CFTR mutations in cystic fibrosis patients from Murcia region (southeastern Spain): implications for genetic testing.
Moya-Quiles MR; Mondéjar-López P; Pastor-Vivero MD; González-Gallego I; Juan-Fita MJ; Egea-Mellado JM; Carbonell P; Casals T; Fernández-Sánchez A; Sánchez-Solís M; Glover G
Clin Genet; 2009 Dec; 76(6):577-9. PubMed ID: 19845690
[No Abstract] [Full Text] [Related]
12. Microarray analysis in cystic fibrosis.
Galvin P; Clarke LA; Harvey S; Amaral MD
J Cyst Fibros; 2004 Aug; 3 Suppl 2():29-33. PubMed ID: 15463921
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis screening.
Shulman LP
J Midwifery Womens Health; 2005; 50(3):205-10. PubMed ID: 15894998
[TBL] [Abstract][Full Text] [Related]
14. Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia.
Banjar H
East Mediterr Health J; 1999 Nov; 5(6):1230-5. PubMed ID: 11924117
[TBL] [Abstract][Full Text] [Related]
15. [From gene to disease; from defective chloride ion transport to cystic fibrosis].
Scheffer H; van den Ouweland AM; Veeze HJ
Ned Tijdschr Geneeskd; 2001 Apr; 145(14):686-7. PubMed ID: 11530706
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive cystic fibrosis mutation epidemiology and haplotype characterization in a southern Italian population.
Castaldo G; Polizzi A; Tomaiuolo R; Cazeneuve C; Girodon E; Santostasi T; Salvatore D; Raia V; Rigillo N; Goossens M; Salvatore F
Ann Hum Genet; 2005 Jan; 69(Pt 1):15-24. PubMed ID: 15638824
[TBL] [Abstract][Full Text] [Related]
17. [Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].
Schwartz M
Ugeskr Laeger; 2003 Feb; 165(9):912-6. PubMed ID: 12661515
[TBL] [Abstract][Full Text] [Related]
18. Biosensor technology for real-time detection of the cystic fibrosis W1282X mutation in CFTR.
Feriotto G; Ferlini A; Ravani A; Calzolari E; Mischiati C; Bianchi N; Gambari R
Hum Mutat; 2001; 18(1):70-81. PubMed ID: 11438995
[TBL] [Abstract][Full Text] [Related]
19. Mutation nomenclature in practice: findings and recommendations from the cystic fibrosis external quality assessment scheme.
Berwouts S; Morris MA; Girodon E; Schwarz M; Stuhrmann M; Dequeker E
Hum Mutat; 2011 Nov; 32(11):1197-203. PubMed ID: 21796730
[TBL] [Abstract][Full Text] [Related]
20. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis.
Gallegos-Orozco JF; E Yurk C; Wang N; Rakela J; Charlton MR; Cutting GR; Balan V
Am J Gastroenterol; 2005 Apr; 100(4):874-8. PubMed ID: 15784035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
